<SEC-DOCUMENT>0001125345-21-000105.txt : 20210916
<SEC-HEADER>0001125345-21-000105.hdr.sgml : 20210916
<ACCEPTANCE-DATETIME>20210916160550
ACCESSION NUMBER:		0001125345-21-000105
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210916
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210916
DATE AS OF CHANGE:		20210916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		211258009

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mgnx-20210916.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:78289c9e-5397-458d-9a56-0ffa873c95ea,g:76248aa6-9b35-4217-801e-055319b3c980,d:5ac0be29a0f44fa9b3dc55a38ef24738--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20210916</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF80L2ZyYWc6ZTJhNjUwZTQ5NGM0NGRjZDkxOWIwZWUxMjI5MjMwYTkvdGFibGU6MzhmZTNkYmNmMTIzNDdhZDk0NzljNTRjODlmYWYzZmEvdGFibGVyYW5nZTozOGZlM2RiY2YxMjM0N2FkOTQ3OWM1NGM4OWZhZjNmYV8yLTEtMS0xLTQ5NzA_21646ba3-64c6-43af-a7ef-e1e20bdb9583">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF80L2ZyYWc6ZTJhNjUwZTQ5NGM0NGRjZDkxOWIwZWUxMjI5MjMwYTkvdGFibGU6MzhmZTNkYmNmMTIzNDdhZDk0NzljNTRjODlmYWYzZmEvdGFibGVyYW5nZTozOGZlM2RiY2YxMjM0N2FkOTQ3OWM1NGM4OWZhZjNmYV8zLTEtMS0xLTQ5NzA_02147a39-c5ff-4528-8855-70a82dda1c41">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20210916.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-16</xbrli:startDate><xbrli:endDate>2021-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0d3875f4a94359b2146d3cb6165fe7_D20210513-20210513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5ac0be29a0f44fa9b3dc55a38ef24738_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ2_56b2e284-3933-4ec7-a2b0-ee363e7729bd">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18yMzI_1743cec5-49d6-4b2b-9ba5-c8788da454e3">September 16, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQx_0353e64f-1aa1-48f4-b940-cac2cc0904ae">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Exact Name of Registrant as Specified in Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.948%"><tr><td style="width:1.0%"></td><td style="width:18.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF8wLTAtMS0xLTQ5NzA_357d7d4a-4367-4f08-8782-0d16b91fc666">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF8wLTMtMS0xLTQ5NzA_c4378769-9617-4071-8520-acfab55e8e36">001-36112</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF8wLTUtMS0xLTQ5NzA_444b48b2-ceec-4af5-88a1-439fa8706b23">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF8zLTAtMS0xLTQ5NzA_48c89ce2-f357-40eb-82ca-31bf61c889cc">9704 Medical Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF80LTAtMS0xLTQ5NzA_f2f61b99-9617-4935-b967-e254dcf7c3b5">Rockville,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF80LTEtMS0xLTQ5NzA_28c9a8f7-770a-4fa5-9efb-e5568283a7f9">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF80LTMtMS0xLTQ5NzA_45f059de-a6d5-44b2-a59e-39ade1995751">20850</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="icf0d3875f4a94359b2146d3cb6165fe7_D20210513-20210513" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQy_bf7778a1-3727-41c3-90b1-078b5c04b289">301</ix:nonNumeric>) <ix:nonNumeric contextRef="icf0d3875f4a94359b2146d3cb6165fe7_D20210513-20210513" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQz_6d0ea807-9b24-40b3-bb48-fe6f6371d3c0">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6NGU4YzBiNzJmYjBiNDIyZmIyYjU5ZDJhMDg3ODk2NmUvdGFibGVyYW5nZTo0ZThjMGI3MmZiMGI0MjJmYjJiNTlkMmEwODc4OTY2ZV8xLTAtMS0xLTQ5NzA_3b716082-92d9-436e-baf5-d7b38b6552c2">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6NGU4YzBiNzJmYjBiNDIyZmIyYjU5ZDJhMDg3ODk2NmUvdGFibGVyYW5nZTo0ZThjMGI3MmZiMGI0MjJmYjJiNTlkMmEwODc4OTY2ZV8xLTEtMS0xLTQ5NzA_0b2492d3-006e-4a4e-b91d-e17e506d50f1">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6NGU4YzBiNzJmYjBiNDIyZmIyYjU5ZDJhMDg3ODk2NmUvdGFibGVyYW5nZTo0ZThjMGI3MmZiMGI0MjJmYjJiNTlkMmEwODc4OTY2ZV8xLTItMS0xLTQ5NzA_246ed697-b34f-4501-9210-b79a61679946">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ0_e5664db5-c2d2-44d9-be52-1c9efe0cd251">&#9744;</ix:nonNumeric> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ1_1a243cec-486e-40b6-a45b-67715bc1cd0c">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ3_3795af97-69e5-4bda-9e21-c4ae35b21c7a">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ4_490ad531-288d-4539-bc95-c0e9821c3b16">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQw_f1decc86-cead-4f16-a793-ff8f9a0b4827">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5ac0be29a0f44fa9b3dc55a38ef24738_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other Events.</span></div></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 16, 2021, MacroGenics, Inc. (the &#8220;Company&#8221;) issued a press release announcing clinical results from Cohort A Part 1 of the Phase 2/3 MAHOGANY study of margetuximab in combination with retifanlimab in gastroesophageal adenocarcinoma (the &#8220;MAHOGANY Study Press Release&#8221;). </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, on September 16, 2021, the Company also issued a press release announcing preliminary clinical results from the Phase 1 cohort expansion of the ongoing MGC018 study (the &#8220;MGC018 Study Press Release&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Copies of the MAHOGANY Study Press Release and MGC018 Study Press Release are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Statements and Exhibits</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibits.</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:21.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="esmomahoganypressrelease.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="esmomahoganypressrelease.htm">MAHOGANY Study Press Release, dated September 16, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="esmomgc018pressrelease.htm">99.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="esmomgc018pressrelease.htm">MGC018 Study Press Release, dated September 16, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div id="i5ac0be29a0f44fa9b3dc55a38ef24738_10"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:  September 16, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></div><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name:</span></div><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vice President and General Counsel</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>esmomahoganypressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2fa659afdc864406a5c8ccf5347f76dd_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2&#47;3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial&#59; enrollment proceeding to Part 2 of Cohort A</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">78% of patients had tumor shrinkage at first scan</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Median duration of response was 10.3 months as of data cutoff </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Margetuximab plus retifanlimab was well tolerated with Grade 3 treatment-related adverse events (TRAEs) in 19% of patients&#59; no Grade 4 TRAEs or treatment-related deaths</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Findings suggest this chemotherapy-free combination, if validated and approved, may be a potential option for first-line HER2+ patients</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:124%">ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) &#8211; MacroGenics, Inc. (NASDAQ&#58; MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced results from Cohort A Part 1 of the Phase 2&#47;3 MAHOGANY clinical trial of margetuximab. MARGENZA&#174; (margetuximab-cmkb) is approved in HER2+ metastatic breast cancer and is being investigated as a potential first-line treatment for patients with HER2+ gastric cancer (GC) or gastroesophageal junction (GEJ) cancer in combination with a checkpoint inhibitor, with or without chemotherapy. The dataset is available in a poster titled </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:124%">&#8220;Margetuximab With Retifanlimab in HER2+, PD-L1+ First-Line Unresectable&#47;Metastatic Gastroesophageal Adenocarcinoma (GEA)&#58; MAHOGANY Cohort A&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:124%">(Poster #1379P) at the 2021 European Society for Medical Oncology (ESMO) Virtual Conference taking place September 16-21, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The efficacy data and safety cutoff dates were July 19, 2021 and August 3, 2021, respectively. In Cohort A Parts 1 and 2, the efficacy and safety of combining margetuximab and retifanlimab (investigational anti-PD-1 monoclonal antibody licensed to Incyte by MacroGenics) is planned to be evaluated in approximately 100 patients whose tumors are HER2+ at the 3+ level by immunohistochemical (IHC) staining, PD-L1+ (combined positive score &#8805;1%) and non-microsatellite instability-high (non-MSI-H). A pre-specified interim analysis assessing efficacy and safety was conducted on the first 40 non-MSI-H patients enrolled in Part 1. These data support advancement to Part 2 with plans to enroll approximately 60 additional response-evaluable non-MSI-H patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A total of 43 HER2 3+ and PD-L1+ patients were enrolled in Cohort A Part 1 and received margetuximab 15 mg&#47;kg plus retifanlimab 375 mg&#47;kg administered intravenously every three weeks. Twenty-five patients (58%) had gastric cancer and 18 patients (42%) had gastroesophageal junction cancer&#59; 36 patients (84%) had metastatic disease at study entry. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MAHOGANY Cohort A Interim Analysis</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Anti-tumor activity was observed in patients treated with margetuximab plus retifanlimab in MAHOGANY Cohort A after the first scan. Tumor shrinkage was observed in 32 of 41 patients (78%) with at least one post-baseline target lesion measurement. Twenty-one of 40 response-evaluable patients achieved an objective response (53%, 95% confidence interval (CI)&#58; 36%-69%), including four confirmed complete responses and 17 confirmed partial responses. The number of confirmed responders by independent assessment exceeded the prespecified futility boundary for the trial, and enrollment is proceeding to Cohort A Part 2.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Disease control was achieved in 29 of 40 patients (73%, CI&#58; 56%-85%) and the median duration of response was 10.3 months (range&#58; 2.1 &#8211; 14.5 months, CI&#58; 4.6 months &#8211; not evaluable (NE)). Median progression-free survival (PFS) was 6.4 months by independent assessment (CI&#58; 6.0 months &#8211; NE)&#59; median overall survival (OS) was not yet reached. At both 12 and 18 months, OS was 85% (CI&#58; 63%-95%).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Antitumor activity was comparable to historical data from the experimental arm of the Trastuzumab for Gastric Cancer (ToGA) study (trastuzumab + chemotherapy&#59; n&#61;294&#59; objective response rate (ORR) of 47%&#59; median duration of response (DOR) of 6.9 months)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and initial data from the control arm (placebo + trastuzumab + chemotherapy) of the KEYNOTE&#8208;811 study (ORR of 52%&#59; median DOR of 9.5 months).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The safety analysis of all 43 patients treated with margetuximab plus retifanlimab suggests the combination was well tolerated in the study population. The most common TRAEs were fatigue (21% Grade 1-2, 0% Grade &#8805;3), infusion-related reaction (19% Grade 1-2, 0% Grade &#8805;3), rash (19% Grade 1-2, 0% Grade &#8805;3), diarrhea (16% Grade 1-2, 2% Grade 3), and pruritus (16% Grade 1-2, 0% Grade &#8805;3). A total of nine Grade 3 TRAEs were reported in eight patients (19%)&#59; no Grade 4 TRAEs were observed. Eight serious TRAEs were reported in seven patients. Infusion-related reactions considered as adverse events (AEs) of special interest occurred in six patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Treatment-emergent AEs of Grade 3 occurred in 18 of 43 patients (42%) of patients. Three of 43 patients (7%) discontinued therapy due to immune-related AEs&#58; renal dysfunction (Grade 3), hepatitis (Grade 3), and diabetic ketoacidosis (Grade 1)&#59; no AEs led to death.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Safety data from MAHOGANY compare favorably to the experimental arm of ToGA in which overall Grade 3-4 AEs were 68% and the treatment-related mortality was 3%.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Initial results from KEYNOTE-811 data presented at the 2021 ASCO Annual Meeting indicated that AEs of Grade 3-5 occurred in 57.1% of patients in the experimental arm (pembrolizumab + trastuzumab + chemotherapy) and in 57.4% of patients in the control arm, AEs leading to death occurred in 3.2% vs 4.6%, and AEs leading to discontinuation of any study drug occurred in 24.4% vs 25.9% of patients, respectively. Despite limitations of cross-study comparisons, regimens containing chemotherapy may have clinically relevant safety differences compared to the chemotherapy-free regimen in MAHOGANY Cohort A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are excited to share our results from the interim analysis of Part 1 of the MAHOGANY Cohort A study at ESMO,&#8221; said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. &#8220;This study is designed to support potential registration of margetuximab in combination with other agents for patients with gastric or gastroesophageal junction cancer as part of our strategy to advance margetuximab in HER2+ cancer. The findings suggest the combination of margetuximab and retifanlimab may potentially provide a chemotherapy-free option as a first-line treatment for patients whose tumors are positive for both HER2 and PD-L1. We are pleased these data support the protocol&#8217;s prespecified advancement into Part 2 of MAHOGANY Cohort A. We plan to discuss these results and future development of the combination in an upcoming scheduled meeting with the FDA.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ESMO Presentation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics&#8217; Cohort A Part 1 MAHOGANY Study poster presentation is available for on-demand viewing on the ESMO website and on the &#8220;Events &#38; Presentations&#8221; page on MacroGenics&#8217; website at http&#58;&#47;&#47;ir.macrogenics.com&#47;events.cfm.</font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Bang YJ, et al., Lancet. 2010&#59; 376 (9742)&#58; 687-697.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Janjigian YY, et al., J Clin Oncol. 2021&#59; 39 (suppl 15)&#58; 4013.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The MAHOGANY Study Design</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MAHOGANY (NCT04082364) is a Phase 2&#47;3 clinical trial in two cohorts designed to evaluate margetuximab in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with advanced or metastatic HER2+ GEJ&#47;GC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cohort A is designed as a single arm study to test margetuximab plus retifanlimab (previously known as MGA012 and INCMGA00012), an investigational anti-PD-1 monoclonal antibody, in patients with HER2+ and PD-L1+ tumors. The primary outcome measure for efficacy is ORR per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cohort B is designed as a randomized trial to test margetuximab plus a checkpoint inhibitor in combination with chemotherapy compared to standard of care therapy of trastuzumab with chemotherapy in patients with HER2+ tumors irrespective of PD-L1 expression. Patients randomized to one of two experimental arms containing a checkpoint inhibitor will receive either retifanlimab or tebotelimab (previously known as MGD013), an investigational DART&#174; molecule targeting PD-1 and LAG-3. The primary outcome measure for efficacy is OS.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 2&#47;3 clinical trial is being conducted at clinical sites globally, in collaboration with Zai Lab, the company&#8217;s regional partner in Greater China. For additional information about the MAHOGANY study, please visit https&#58;&#47;&#47;clinicaltrials.gov&#47;ct2&#47;show&#47;NCT04082364.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Gastric and Gastroesophageal Junction Cancer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancer of the stomach (gastric cancer, GC), or the gastroesophageal junction (GEJ) where the esophagus joins the stomach, is collectively known as gastroesophageal adenocarcinoma and is the fifth most common tumor type worldwide. Both GC and GEJ cancer are often diagnosed at an advanced stage and therefore have very poor prognosis, with a 5-year survival of 5-20%. Chemotherapy is the standard of care for first-line therapy and may be combined with trastuzumab for the approximately 20% of patients whose tumors are HER2+.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Margetuximab</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MARGENZA&#174; (margetuximab-cmkb) is approved in HER2+ metastatic breast cancer and is being investigated as a potential first-line treatment for patients with HER2+ GC or GEJ cancer in combination with a checkpoint inhibitor, with or without chemotherapy. Margetuximab is an Fc-engineered monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors.  Through MacroGenics&#8217; Fc Optimization technology, margetuximab has been engineered to enhance the engagement of the immune system. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Margetuximab is also being evaluated in combination with tebotelimab (PD-1 &#215; LAG-3 bispecific DART&#174; molecule) in various HER2+ tumors (NCT03219268). MacroGenics is partnered with Zai Lab for the development and commercialization of margetuximab in Greater China. For more information, please visit </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.clinicaltrials.gov</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Retifanlimab</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Retifanlimab is an investigational, humanized, proprietary anti-PD-1 monoclonal antibody being developed for use as monotherapy as well as in combination with other potential cancer therapeutics. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Retifanlimab was licensed to Incyte Corporation in 2017 under an exclusive global collaboration and license agreement. MacroGenics retains the right to develop its pipeline molecules with retifanlimab. Incyte is pursuing development of retifanlimab monotherapy in four potentially registration-directed trials for patients with MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer and non-small cell lung cancer. Incyte and MacroGenics are each conducting multiple studies of retifanlimab in combination with other agents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Tebotelimab</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tebotelimab is an investigational, first-in-class bispecific DART molecule designed to provide co-blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About MacroGenics, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cautionary Note on Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, including enrollment in clinical trials, commercial prospects of or product revenues from MARGENZA, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and other statements containing the words &#34;subject to&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;plan&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;estimate&#34;, &#34;potential, &#34; &#34;project&#34;, &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;would&#34;, &#34;could&#34;, &#34;can&#34;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA&#8217;s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTACTS&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chris James, M.D., Vice President, Investor Relations &#38; Corporate Communications</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jim Karrels, Senior Vice President, CFO</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-301-251-5172, info&#64;macrogenics.com</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>esmomgc018pressrelease.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibfd6e5c888814892a552f2d7dd28a1f3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Metastatic castration-resistant prostate cancer (mCRPC)&#58; 21 of 39 patients (54%) achieved &#8805; 50% prostate-specific antigen (PSA) reduction&#59; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity&#59; 4 of 16 (25%) achieved partial responses (two confirmed and two unconfirmed)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Non-small cell lung cancer (NSCLC)&#58; 13 of 16 (81%) evaluable patients had anti-tumor activity&#59; 4 of 16 (25%) achieved unconfirmed partial responses</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Manageable safety profile overall, with low rate (7%) of discontinuation due to treatment-related adverse events (TRAEs)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROCKVILLE, MD, Sept 16, 2021 (GLOBE NEWSWIRE)&#8212;MacroGenics, Inc. (NASDAQ&#58; MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data from dose expansion cohorts of the Company&#8217;s ongoing Phase 1 clinical trial of MGC018. This investigational antibody-drug conjugate (ADC) was designed to deliver a DNA-alkylating duocarmycin payload to both dividing and non-dividing cells in a B7-H3-dependent manner. The dataset is being presented in a poster titled </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors&#58; Preliminary Results of Phase 1 Cohort Expansion&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Poster #620P) at the 2021 European Society for Medical Oncology (ESMO) Virtual Conference taking place September 16-21, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cohort Expansion Results Update</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of the August 16, 2021 data cut-off, a total of 86 patients with advanced solid tumors were enrolled in the cohort expansion of MGC018 at the recommended Phase 2 dose (RP2D) of 3.0 mg&#47;kg, administered intravenously every three weeks. The enrollment includes 40 patients with mCRPC, 21 patients with NSCLC, 16 patients with triple negative breast cancer (TNBC) and nine patients with melanoma. In addition, enrollment of patients with squamous cell carcinoma of the head and neck (SCCHN) was recently initiated. The safety analysis both in the poster and below includes all enrolled patients, whereas the efficacy analysis was limited to mCRPC and NSCLC patients, as enrollment continues in the other tumor cohorts.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the cohort expansion, tumor response by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) was evaluated every nine weeks for all patients and PSA was assessed every three weeks in mCRPC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Preliminary Anti-tumor Results for mCRPC Cohort Expansion</font></div><div><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As of the August 16, 2021 data cut-off, all 40 patients in the mCRPC cohort expansion had been enrolled. Patients had previously received a median of three prior therapies for advanced disease, with all 40 patients having received both chemotherapy and next-generation hormonal therapy. The median B7-H3 H-score for all mCRPC patients was 223.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A total of 39 mCRPC patients were evaluable for PSA response. Reductions in PSA levels of &#8805; 50% were observed in 21 of 39 patients (54%). Twenty-four of the 39 patients (62%) remained on treatment as of the data cut-off. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Of the 40 patients in the mCRPC cohort, 16 of the 23 patients with measurable disease were evaluable for tumor response by RECIST as of the data cut-off. Ten of these 16 patients (63%) had reductions in their target lesion sums from baseline. Four patients (25%) demonstrated a partial response (PR), consisting of two confirmed and two unconfirmed PRs. Treatment was ongoing in six of 16 patients with evaluable tumor response as of the data cut-off.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Preliminary Anti-tumor Results for NSCLC Cohort Expansion</font></div><div><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As of the August 16, 2021 data cut-off, the NSCLC cohort expansion had been fully enrolled with 21 patients. Patients had previously received a median of two prior therapies for advanced disease, with 15 (71%) having previously received anti-PD-1&#47;PD-L1 therapy. The median B7-H3 H-score for these patients was 139.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A total of 16 NSCLC patients were evaluable for tumor response by RECIST. Thirteen of 16 (81%) patients had reductions in their target lesion sums from baseline. Four of these 16 patients (25%) experienced unconfirmed partial responses. Another one of these 16 patients experienced a 30% reduction in target lesions&#59; however, the patient&#8217;s non-target lesions were not evaluated due to an obstruction of the bronchus and overall response was not evaluable. Treatment was ongoing in seven of 16 patients as of the data cut-off.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Preliminary Safety Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The safety analysis includes all 86 patients enrolled in the cohort expansion as of the August 16, 2021 data cut-off. The median number of doses received by mCRPC patients was 3.5 (range&#58; 1-8)&#59; those with NSCLC received 3.0 (range&#58; 1-7). Adverse events for the dose expansion cohorts of 3 mg&#47;kg were generally consistent with those previously reported at ASCO 2021. TRAEs included hematologic and skin toxicities that have been clinically manageable to date. In the cohort expansion study overall, at least one TRAE of any grade was experienced by 78 of 86 patients (91%), with 43 of 86 patients (50%) experiencing a Grade &#8805;3 TRAE.  There were two Grade 5 fatal events&#58; one from an unknown cause and one due to SARS-CoV-2.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The most common TRAEs were fatigue (37% all grades&#59; 1% Grade &#8805;3), neutropenia (34% all grades&#59; 22% Grade &#8805;3), palmar plantar erythrodysesthesia syndrome (31% all grades&#59; 4% Grade &#8805;3), pleural effusion (23% all grades&#59; 1% Grade &#8805;3), nausea (22% all grades&#59; 1% Grade &#8805;3), asthenia (20% all grades&#59; 5% Grade &#8805;3) and thrombocytopenia (14% all grades&#59; 7% Grade &#8805;3). The overall results have demonstrated a manageable safety profile with a low rate of treatment discontinuation due to TRAEs&#58; only six of 86 (7%) patients had discontinued therapy in the cohort expansion as of the data cut-off date due to TRAEs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are highly encouraged by the growing data from our ongoing Phase 1 study of MGC018,&#8221; said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. &#8220;Consistent with previously presented data, we observed PSA reductions of 50% or greater in 54% of patients with metastatic castration-resistant prostate cancer. And now, we are particularly pleased to see partial responses emerge &#8211; both confirmed and unconfirmed &#8211; in mCRPC and NSCLC patients, with encouraging anti-tumor activity observed in the majority of patients for both tumor types. Also, we are very pleased with the evolving safety profile of MGC018, which showed neutropenia as the only Grade 3 or higher TRAE that exceeded a rate of 10% in this trial. Finally, further optimization of patient management has resulted in a low rate of MGC018 discontinuation due to TRAEs as of the data cutoff. Enrollment is ongoing in the TNBC, SCCHN, and melanoma cohorts and we look forward to providing further updates on patients in these cohorts, as well as patients in the mCRPC and NSCLC cohorts, at subsequent scientific conferences.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ESMO Presentation</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics&#8217; MGC018 poster presentation is available for on-demand viewing on the ESMO website and on the &#8220;Events &#38; Presentations&#8221; page on MacroGenics&#8217; website at http&#58;&#47;&#47;ir.macrogenics.com&#47;events.cfm.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About MGC018</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MGC018 is an ADC comprised of an anti-B7-H3 humanized IgG1&#47;kappa monoclonal antibody conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA&#59; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of &#126;2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. B7-H3 is a molecule highly expressed on many solid tumors and associated with a poor clinical outcome. MGC018 is being evaluated in a Phase 1 study (NCT03729596). MacroGenics retains worldwide rights to MGC018.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About MacroGenics, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cautionary Note on Forward-Looking Statements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, including enrollment in clinical trials, commercial prospects of or product revenues from MARGENZA&#174;, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and other statements containing the words &#34;subject to&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;plan&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;estimate&#34;, &#8220;potential,&#8221; &#34;project&#34;, &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;would&#34;, &#34;could&#34;, &#34;can&#34;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA&#8217;s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTACTS&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chris James, M.D., Vice President, Investor Relations &#38; Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jim Karrels, Senior Vice President, CFO</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-301-251-5172, info&#64;macrogenics.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mgnx-20210916.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:78289c9e-5397-458d-9a56-0ffa873c95ea,g:76248aa6-9b35-4217-801e-055319b3c980-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20210916" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20210916">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210916_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210916_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://macrogenics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mgnx-20210916_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:78289c9e-5397-458d-9a56-0ffa873c95ea,g:76248aa6-9b35-4217-801e-055319b3c980-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_6b83d7c6-308f-4d19-b1d7-f803e4893ce3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_36e74dc7-5362-412f-9f02-d454bb630308_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_55814638-a8b5-4da2-a4f3-6270850464a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5c9a8790-f5a1-4740-bf50-556b48a93ea4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_214bfc63-628e-4cde-b3cc-467de8010e2c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_248be297-d632-4f7f-8984-9fa93c092a92_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8dc9af22-4611-4ed8-a849-2865fdfc9405_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_2336567b-d6d7-4a8a-baf5-89c686bbc2bc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_353fa947-8ab0-40f2-a4dd-9c949351c9c5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_be717a35-1640-4351-a344-732766f5cae4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ddaf4beb-2f01-46e2-9643-c7819d60a4f2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ab9dead8-c873-4397-91e6-0033cb7f32a8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_92450e96-7310-466b-bff8-4ce1a472412c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1d278808-b348-4ebb-a1a3-0f7f8aaa55fe_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a41554f5-d973-4345-837c-294297d3650f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cf866ce0-e20b-4dca-a369-e6985eda3d02_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8417ba18-26d0-4474-a7ab-a60aa27f2d76_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_31018d1b-8829-454a-91bb-e8662fefe401_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_70d2a68a-2f9d-47e6-8ef6-89c0d063c581_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e53fbe0f-066e-4313-8f32-df6441f4cf17_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_43606018-6081-4383-aafe-fc3c79733222_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_09d1665d-7bd7-435f-8aa7-46cb131ba669_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7780f6ee-3a58-49dd-bf00-cc3b9c1727ec_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mgnx-20210916_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:78289c9e-5397-458d-9a56-0ffa873c95ea,g:76248aa6-9b35-4217-801e-055319b3c980-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20210916.xsd#Cover"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b73c5bdd-3202-4973-9d18-71ae18dd7ed7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_DocumentType_b73c5bdd-3202-4973-9d18-71ae18dd7ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b7b525d9-21a8-4b5e-b598-3eba35930c1e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_DocumentPeriodEndDate_b7b525d9-21a8-4b5e-b598-3eba35930c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_61b0bbb5-624d-49bc-bd82-7f3e31983dee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityRegistrantName_61b0bbb5-624d-49bc-bd82-7f3e31983dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4726eaf5-cade-4244-875a-7ca5314f393c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4726eaf5-cade-4244-875a-7ca5314f393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ae9de9d3-1097-4fad-a9e5-6288746eb694" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityFileNumber_ae9de9d3-1097-4fad-a9e5-6288746eb694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1186890a-df4d-4a73-9775-ac3d8d0c7b51" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityTaxIdentificationNumber_1186890a-df4d-4a73-9775-ac3d8d0c7b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e57efecc-b073-4d54-9246-738281b471a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityAddressAddressLine1_e57efecc-b073-4d54-9246-738281b471a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e72babf2-72f6-42aa-9ac4-a72221188b42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityAddressCityOrTown_e72babf2-72f6-42aa-9ac4-a72221188b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5e66d916-c193-4e94-987b-accf13762560" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityAddressStateOrProvince_5e66d916-c193-4e94-987b-accf13762560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_56c40f3d-6fa1-4f22-8f9c-a5c40bc0bcda" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityAddressPostalZipCode_56c40f3d-6fa1-4f22-8f9c-a5c40bc0bcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d7e4ec1a-8683-422c-b76b-c8c5ced25a74" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_CityAreaCode_d7e4ec1a-8683-422c-b76b-c8c5ced25a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_41a3eca9-8578-48b3-b4ee-54c23214b4f1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_LocalPhoneNumber_41a3eca9-8578-48b3-b4ee-54c23214b4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_de00f823-5684-446e-abfb-468ca2625abc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_Security12bTitle_de00f823-5684-446e-abfb-468ca2625abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ee5be617-0b4a-4259-98bd-ff7205b6de7f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_TradingSymbol_ee5be617-0b4a-4259-98bd-ff7205b6de7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_30443a1d-9ee8-4214-8e58-2b1d2d88b582" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_SecurityExchangeName_30443a1d-9ee8-4214-8e58-2b1d2d88b582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_162b09f0-0752-451a-80a0-4dcb186c9148" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_WrittenCommunications_162b09f0-0752-451a-80a0-4dcb186c9148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_9ee070f1-f338-4c62-a0f5-864ef691be42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_SolicitingMaterial_9ee070f1-f338-4c62-a0f5-864ef691be42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e68ab16d-4583-4da6-a0fa-cb91a40d66f7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_PreCommencementTenderOffer_e68ab16d-4583-4da6-a0fa-cb91a40d66f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_bbc92fb2-314f-486a-b5ed-e160db0b98e5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_bbc92fb2-314f-486a-b5ed-e160db0b98e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a8041691-5b31-499d-b7e1-245f6cbbc7af" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityEmergingGrowthCompany_a8041691-5b31-499d-b7e1-245f6cbbc7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_90b4c912-4445-414c-bf42-036b8f9322e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_EntityCentralIndexKey_90b4c912-4445-414c-bf42-036b8f9322e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d655c954-1909-49ad-9ed5-7bd258a14edd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_AmendmentFlag_d655c954-1909-49ad-9ed5-7bd258a14edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9a9ef603-1bc5-40c2-ac6e-d93de777b2cb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e495e9c-74ec-4e54-b113-637c8795b12e" xlink:to="loc_dei_CurrentFiscalYearEndDate_9a9ef603-1bc5-40c2-ac6e-d93de777b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>mgnx-20210916_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20210916.xsd" xlink:type="simple"/>
    <context id="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-09-16</startDate>
            <endDate>2021-09-16</endDate>
        </period>
    </context>
    <context id="icf0d3875f4a94359b2146d3cb6165fe7_D20210513-20210513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF80L2ZyYWc6ZTJhNjUwZTQ5NGM0NGRjZDkxOWIwZWUxMjI5MjMwYTkvdGFibGU6MzhmZTNkYmNmMTIzNDdhZDk0NzljNTRjODlmYWYzZmEvdGFibGVyYW5nZTozOGZlM2RiY2YxMjM0N2FkOTQ3OWM1NGM4OWZhZjNmYV8yLTEtMS0xLTQ5NzA_21646ba3-64c6-43af-a7ef-e1e20bdb9583">0001125345</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF80L2ZyYWc6ZTJhNjUwZTQ5NGM0NGRjZDkxOWIwZWUxMjI5MjMwYTkvdGFibGU6MzhmZTNkYmNmMTIzNDdhZDk0NzljNTRjODlmYWYzZmEvdGFibGVyYW5nZTozOGZlM2RiY2YxMjM0N2FkOTQ3OWM1NGM4OWZhZjNmYV8zLTEtMS0xLTQ5NzA_02147a39-c5ff-4528-8855-70a82dda1c41">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ2_56b2e284-3933-4ec7-a2b0-ee363e7729bd">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18yMzI_1743cec5-49d6-4b2b-9ba5-c8788da454e3">2021-09-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQx_0353e64f-1aa1-48f4-b940-cac2cc0904ae">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF8wLTAtMS0xLTQ5NzA_357d7d4a-4367-4f08-8782-0d16b91fc666">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF8wLTMtMS0xLTQ5NzA_c4378769-9617-4071-8520-acfab55e8e36">001-36112</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF8wLTUtMS0xLTQ5NzA_444b48b2-ceec-4af5-88a1-439fa8706b23">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF8zLTAtMS0xLTQ5NzA_48c89ce2-f357-40eb-82ca-31bf61c889cc">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF80LTAtMS0xLTQ5NzA_f2f61b99-9617-4935-b967-e254dcf7c3b5">Rockville,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF80LTEtMS0xLTQ5NzA_28c9a8f7-770a-4fa5-9efb-e5568283a7f9">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6Njk2ZjA3M2QyZDA2NDllNDljYzhjZjQxNGRmOWM0MWQvdGFibGVyYW5nZTo2OTZmMDczZDJkMDY0OWU0OWNjOGNmNDE0ZGY5YzQxZF80LTMtMS0xLTQ5NzA_45f059de-a6d5-44b2-a59e-39ade1995751">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icf0d3875f4a94359b2146d3cb6165fe7_D20210513-20210513"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQy_bf7778a1-3727-41c3-90b1-078b5c04b289">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icf0d3875f4a94359b2146d3cb6165fe7_D20210513-20210513"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQz_6d0ea807-9b24-40b3-bb48-fe6f6371d3c0">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6NGU4YzBiNzJmYjBiNDIyZmIyYjU5ZDJhMDg3ODk2NmUvdGFibGVyYW5nZTo0ZThjMGI3MmZiMGI0MjJmYjJiNTlkMmEwODc4OTY2ZV8xLTAtMS0xLTQ5NzA_3b716082-92d9-436e-baf5-d7b38b6552c2">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6NGU4YzBiNzJmYjBiNDIyZmIyYjU5ZDJhMDg3ODk2NmUvdGFibGVyYW5nZTo0ZThjMGI3MmZiMGI0MjJmYjJiNTlkMmEwODc4OTY2ZV8xLTEtMS0xLTQ5NzA_0b2492d3-006e-4a4e-b91d-e17e506d50f1">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGFibGU6NGU4YzBiNzJmYjBiNDIyZmIyYjU5ZDJhMDg3ODk2NmUvdGFibGVyYW5nZTo0ZThjMGI3MmZiMGI0MjJmYjJiNTlkMmEwODc4OTY2ZV8xLTItMS0xLTQ5NzA_246ed697-b34f-4501-9210-b79a61679946">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ0_e5664db5-c2d2-44d9-be52-1c9efe0cd251">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ1_1a243cec-486e-40b6-a45b-67715bc1cd0c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ3_3795af97-69e5-4bda-9e21-c4ae35b21c7a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQ4_490ad531-288d-4539-bc95-c0e9821c3b16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i037c4f62b37e415ca55fef5a90632391_D20210916-20210916"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhYzBiZTI5YTBmNDRmYTliM2RjNTVhMzhlZjI0NzM4L3NlYzo1YWMwYmUyOWEwZjQ0ZmE5YjNkYzU1YTM4ZWYyNDczOF8xL2ZyYWc6ODQxMTFiY2FmMGYyNDM5NmI0M2YxMzU0NTc4NjY0M2MvdGV4dHJlZ2lvbjo4NDExMWJjYWYwZjI0Mzk2YjQzZjEzNTQ1Nzg2NjQzY18xNjQw_f1decc86-cead-4f16-a793-ff8f9a0b4827">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140706479712952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 16, 2021</div></th>
<th class="th"><div>May 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 16,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">251-5172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M W!_I90Y#NP^M?Q=8O O4$L#!!0    ( +> ,%.?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
MMX P4ZK$(A8S 0  (@(   \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J
M'[ 6M"$-45Y VY"F#8V)]]"ZU"*)*\>%C:^?VZH:TE[VE-S9NMQ=%A?BTX'H
ME'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8
MM;:<W@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(
M\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#
M+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U
M!D.LL8DF"=9#;E9T!N[RZ .;<L@F:NJF*9ZC#GA3#O9&3R54&*!\4YFHO/93
M;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    ( +> ,%,D'INB
MK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,
MA:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@
MMO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<
M//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P
M6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "W@#!3
M99!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\2
M95LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&P
MZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5
M,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0
MBJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*I
ML0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U
M[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_
M 5!+ 0(4 Q0    ( +> ,%,'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ MX P4\13;-KO    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ MX P4YE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " "W@#!3JD0N=48$  "C$   &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ MX P4Y^@&_"Q @  X@P   T              ( !B@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "W@#!3EXJ[',     3 @  "P
M@ %F#P  7W)E;',O+G)E;'-02P$"% ,4    " "W@#!3JL0B%C,!   B @
M#P              @ %/$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MMX P4R0>FZ*M    ^ $  !H              ( !KQ$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ MX P4V60>9(9 0  SP,  !,
M             ( !E!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  WA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mgnx-20210916.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mgnx-20210916.htm">mgnx-20210916.htm</File>
    <File>esmomahoganypressrelease.htm</File>
    <File>esmomgc018pressrelease.htm</File>
    <File>mgnx-20210916.xsd</File>
    <File>mgnx-20210916_lab.xml</File>
    <File>mgnx-20210916_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20210916.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 2,
   "dts": {
    "inline": {
     "local": [
      "mgnx-20210916.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20210916_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20210916_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20210916.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20210916",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210916.htm",
      "contextRef": "i037c4f62b37e415ca55fef5a90632391_D20210916-20210916",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://macrogenics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210916.htm",
      "contextRef": "i037c4f62b37e415ca55fef5a90632391_D20210916-20210916",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001125345-21-000105-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-21-000105-xbrl.zip
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M:Y.].VV]]7YFKV@OWN)>_"L!;N-!BJLB9KHH=_I3SAL0_63'BE?.@#F[TLQ
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M=<JLQUZ'LBQ%]U^(00;M_PSI?DN@V_D\H/N+#XSV^YLFXV A(S"8;U$+IFV
MLE['9OGW!ZQQN-_OVFSDX&"_-3C<7]W[QT#E[M]"Y3=^\D%,,0;Z^^\EJ=_0
MP3-35=<FW\$2_) UT'!%S-NS-.]WO-YF8?N1S?R1S?S/S.^M"[F-T3HE"/R(
M@<8&ZYVOLG$YO.WT.P?=WJ!OJKIK1>.U6G%TDQ<2H!N:^JJ'D!<X?MH1^"ME
MULV_6"IN$6V(_3HU6<8;.!N]H66>#9^>1UJ@,=>1(QIB-6;$*79B7#WTX='_
M^416HS''LYJFZNXND0MR9B[.3CHV"7U^.<1?'?A-L5#VIXIJFY52*:?,WZD[
M-/Z0\=[FX#IC30TP"C 8S^N3B 6*4E-8.Z;AYH [K_/4Z<CP*7+C4 ETP7T<
M^H8@UJWQN!K7H^'YS2WSVMX33)I;UOAEE344$!L\L#]0HDG>-[/&>B%>*^^5
M2),;.0)AQ,*HT)QS@<W+&Z&'Z$3Q5GO9P"O681:J#)=15 79!R.'MJ2C#2Z*
M_=A=L62VH U57#W.6(F=;5C\0D117N[*N*!X1T6$L/Z+@YWF#TK4*>"<]1)T
M>G)]:T_EQ#+B01;E97HX*Q(M%)>W)V<  ?^<F-P\/3Z_73D"5;=F^9FDL@8=
M?,"B$3J%FDTC.<;H3M/P=@3.JE0.=__;%^ OC)MY3 ./B171%0R2T<YAN"HQ
MQX[.*).LV' &4M)FK[!XI:PY%PEL36SZAY&RM!H))(W=M%$><))ACN2TZIK7
MFB^"%JK;4WEO'J>&%'HF%_07Q_X_9@98#^A.B'YY]0Y*QLIII3=Y9-'4]CQB
M$FS0]29@:D-N&AP$/YBQ1K4&OLG.AJ!P;'7JIP[0+6;<J&IFVX U^ ":4+M#
M-%&X4%KRI$6IX%;Z]VO7?9C3@J;,>8+5%DX5A"GV2I=SSA9212'X1+S-?L&
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M+Q2^[C6-EI+F!/1I"R_PI,8ZT'*5 SC8561%Y"H\E*VAX_?$SP0&]6R<- V
MW3&7"-A7+*=+$;!>(1H'.:3: 6$_[>SWLNKB\HJ"@0I1"+[+C SVF^D/+G';
MEF<MMR69W2.IOPJ0'APWLDS]_SLWHB>L).XG0I,BI$BTC)%8C1I!Y9?R(ZCQ
M%[ C;U=L['MLDG<N ;<Z/=WPY4G7XX@:/[SQ/I,&6?MO42!O</A]4""8=CO:
M_!)@Y)QLFBL+@U5QJ%42^A, N!Y:&0RA8#BZXJO^9!&I!\NU\;%!/+=VQN9<
M4@Q WJH]\Y:;F\UL.6MFYA3N6<UW$U49;4H1MP=9F6(?C2C3E4](G<= =;>>
M,[=Q:F)_5MA(T]5E:OF3@M63X9(^A>!4A5G&\*^,T@^FU:()X-<VK^/ ^SL^
MZGJ37I>Z:F6GFNG*WTU'RL\"_A8LQ@4GL:E0:*BB7T>>BW4QXJ '2$YE/%6N
MOMP]V+2VE<\HS5GG&.N9*.'9'K./^&G8+C>6]:W[JU"#.FMJ#=,&P.2>''MB
M.^)D)N^EY2T23&/;:8;7(]M. SE0B;.4=R 09LN<J@#<91&([)8$;3YH'W&0
MHG0@AL,5*>L:RY(7YH_JZBR5JX 4G M=>TD9=_A455M)<$.I5@(ZVA"=E:J)
MTU0&%C2:2(=KV3]8SF-O' *_G<_<&:Q\B\"V ;U<$A,O>787^@YXX9X@Q4@=
MQR97;1_:%1-);L?>E+U#VBQC/U2HB&]C,X<\9$%4DJ /WSJ@O!Y>77='YFVW
M_SWCU/W&&QG*DIL()-^I$TL/$M-32&!CL/^$[9AOT[DA[\F2^'%WL2IR*D_%
M6F+0SNJ@?G_-J$2&X)]4DHKANH1*%_DL-<$"EDP.$W-EBSC /=%.O-5)=];-
M&2K$7"$EO@M6V(W^X#//0 J [=-6/^=Y29OD T.<*R-V5T;82 @'C,;&7^2E
MM+PUTMI?&6Q1K^&4.1A@:UX*T:)[6RULRJ[NL2"PK3SX/8T6K!2ET0 J7&P&
M ^4.C1;IJJ>HRO^+SP#[)K@S^+36_K]G=Z[L_0Y@ U.;X1L.47R03UP<8R2)
M99J:.3<)5"T.S$Z7&A<<')>%O(XK7N/J=2"N?81UXA<#19MVQ%GOI-?!0/L/
M=?MQSP!IY>CT@N>H>TAZPFUSM.2<&FZI;BB@/0+ &[E'F[^L2#@FI_PDO.24
M^Z!3THM=:/Y*:2WZLMY$8MK4'S'GY4F@3,;](I0I;9&<DRUT94JM:0%4D0)G
MYL-Z$)M-6+=R%TVB7SY6UEC6ULULKL+=I^W@6&U<:29I.:DDWYN4OV@(A%@%
M[\@.SA<)AQ9A9JK3<OFG/*5C#\1*3,@AYW*S5:4G8C[3_DQD%%,$+?AVA4.V
M=@M" [HWTE-<&[MX9A+J@Z]4P)!3HHF'*^;S@ 9R(PU"*O!@4(P.(O'4!D1)
M#G+\49:!ASNL@RV&HAD72@GAREZ5)F2YBO6G\&H-N#!Q/&V4GEOQ"CU)->*.
MX%IMA^^UK M7+(X^A-A#8V[I:N8R9<6"<%UG3GG&@GL2:(7EY&%6(J&MK\ZI
M?(Q_UZ<8:^6JQP"E"JC.;P4=(O-I%+?5^E6C1]9;:F#YD5C_D5C_3G*?_*Z
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M?,?S.8P.7NP'4Z_ U(TYIK8563=TS<2F1H"I)9U@0Z429K;++%7E!I<UL<U
ML*P10C^X^K6XNLTF]7PKQTXU^ >+K\SB1W,LKBB*I1@6Q3;G-E:8JV+#$!&"
M;(KR(4FSJ-BQUS!1@1)B3^L.'G^\@^)S][9;G/+O6X\Q4H;?2#T(D3%L)7T>
MH6_CR(L=+TLE0LPQYVW<""]^1NWP4/15PN'0BT6U7)HR%D8+92+]Z=64Z'MG
MP?K!(:H-1WXXY='["M.EJU35O%9'S;"X2%IR/3,#>C:.DE+_V7CDW3;]B!-7
M=B2V'2?B<9Q_[ $ Y,.)N,^)N+@9_"F&;9@VI]B%,!#\9&YA@]H,R\1R-6(;
M\- N;)FZI* &=P1GH4K*::@:>6>O% VN2_!6,CYI??>O)W<5^-J*VN%Y\"%U
M]TF==%/J7 K"99FSZ-2456R9FHXY517'=G5;MM3"UD%HGYYYOL\WGR!F#W*7
M?@J&?7!",>?H-!!H1?O0TDNK]C_8^EZVOE%#;M@F,UP=Z[K$L.(R%9O<M3!7
M5<V@ALQTURQL-5@T]5G@O(3M,!_O*F6[.#^+$"SA\?T0I,'O>J./7/F*'#Z?
M5E145U)-AV.F.2I6%(MBIIH<RR9S.#%-55=)88M*ABH]/-WR!.9]#?6])'C-
M.4OD2O8C4)S>"'S$VH3;XP0<1-1R(23D\?)DP/M<-8@0$C+TZ3992^G>\7,5
M K^Y2KS%6_576_-_Q"CA/A_UPX"C(,T$;2+@"W\LB(M8Q!D0W^&7Q57YTM91
M=[=QE]Y]S,&':WI7.,C;L-AWJVF?5+8R/;%<7==%/EK6*?BXQ):Q*5D$2[IA
MJ;8$JM, 9T"6;I5F?;JSWNZ)5-D+07WL"]Y\Q_L.3Z+,Q8GF2)P9DHX!>0K$
M_):,+4LQL,LU5Y-U MB4P(BI!*M$7[XU]E95T=HKYU;3/<TP06PT\L&>@;EX
M.T _L$9K8P?"+1[E-5H1RG_F7@%H?E?49@4][J!#$5:A/18GZ" ML;U=K?5$
M:SA?KV7"DG*? D<9R&I15]/(81V,>:W*.TK-)8\ *Z-%)>QTPYH5KXM"\/)L
MQ:];RP:^3E'*XI.'%K/):E%5EI=5/;J8S2Q**GW^^C!:)-(3*KFN(M2<)B+%
M4@8?%L6A[SEHQEOY4_!;%SQ\8,9FK?%J6]P)D)7.VWUD^RR.5PC??Q7D1"QU
M=0^G0ROT-^Z(?1Z(FER)_;R8FQ7ZIES%9R=A0"&>]SWXRY76O#^8OH7:7/$M
MQ=[/PY6+0]873#'EAFU*J)4JAG?I5.>)I=TC1<#6O/@V[ S@LUJ?=H?U:6=P
MI':KW_J-:D]N54]I<WAT,[$D==O]06.W+C>&70\^I<9 C/'-:[;]T\:P=MZJ
MVDJKW:'='P#CS2),2P<'T*#8I(XI*C$YMD1%CZ-;LF%IJDIM6M@2Q18@#8=)
M:)]NHA&+T!GSQQS]+]AI@D;B8'W_<36:ZQ&2M69B7UU,<KN0F84/&5E!1FY<
M5P+A*HB'C"4)Q$-A"LB(21S,B<Y527-4R26%K<9N\Y]U"<!/9*!?23IN;M8)
MHW][GVYF8&:'8]_M4;#7%J#Z_/Z<HG%',W5LR8JX[T<B8&Z(A"W=9!K1=--4
M-.&$Q0[[%^WZH<5\"$E]"$I1@T6G/+E_3^-6\GMQ:*X6J3IC=2\0E6/IO29O
M,V,T#_KZP*STN7V:I@38:!2%H\@3E:M6.$$6]\-SD6H1#T4&!AGX;^1ZO@A#
MO!AYXKXWASLBQQ![P[&?L("'X]B?HI@E7NQ.TYYYA] "1<-F!;#B071U\&X,
MXT2(!=/9,S?T87+13^RQ>Z(2-$8;,>=HEP<\ A:J!]!WG&4VMHNTF('[J;PB
MPF5 3OX7H4#IVO#_XLK/"D,?9,X/$R#J=?UW#,H/*"C<OW&05UC&[U(!/BEU
M+9UP5=,4QU*Q31V*%05\98NK%!/;Y"Z7;(>*_=???S-U1?E\4UNA'(U N>MX
MG,O '8QGN5B%JCFS"RZ_EKL3%S-L$!U5=@X0E:4B-%R>R/Q@Y1NL? B^CPV(
M#'H-T%Z@PMZG)_PD/B8GA-'T'@.L&,*5E2P-,T6UL*;K1+5L8CN2O9R/KW"(
MACD2ES Q41@F]!H?SUTO<LG%BE3,6GXP\LJ,O!]QH8_%]8/I34_"P$8MU_T5
M]Q3E$UDW5>:":ZF97,6*Y3!L<DJPK3 NJQ8EMLZ6,S3@$MO7D+F:AB:*@].-
MDI78.VM[+X-_L'-*@7H<CWGT2S.U<J*8$G-4F6!J& [$2S)X&[8)SH?$30-8
M6K;$':'/S-0RV(,->S6FSML^0&L_9A]5G5?VZ]M K0?B!(*(>:;(3H,A .L4
MG?=Y>G3O1J0"<0^ "*@7D/=0+PK/D[X@PDA$+RQ&#G=ABO3Z$(%_I$CJ+*BY
MX>YE]W#):$/02/^<>GVSQC -D&<D+A\1^]_I2(1:F"X8:]'E7I>#"H)>];LV
M;!&]-T+5EB#]16_2NEN_966P,\!V4[@J&5B_GFH[/W&)PVW;T+#-&:@V%Y#*
M=%/&KFNX)I,LQ:#Z4M7VWMBQ[MZA"41QXD*UXMW*??1!::3I,% :09@J[G',
MTU; Q7F&1;P[P$MS'=EEP8)%T[G\J9@\?6&$D(4 U@9/(G[FQ= /5!$+;.')
M,]L6]YF(QN+] 0Z+G#C+K3C+RD7D#799+G)=QQ010I<T7$*SZ]<*C\(,]'+$
M?2;*=V]=-'R5+D])+%UU858<^N/D=I?[[B9^Z 7)^N4%R?W+<Z0CUN/8BC@[
MQ<P%G5EF_CF;QH72B]ZB?#MS>8]=%2H*0\^(V4DY'@^!SZ:%=U350]2B3)^_
M_,:@145?[=:GQY_3>ZU33V2E2H=ZPH?(*(KJUY<YRG7)SJ^X,J+"RK)K%&KB
M)LVXN.P$^-)M@L?)U>VZOVLX&HSCQ'.G+[_9<!,_BXU1*T"WKZ?<1 UF1^$N
MA_ @WA273A31AM#FO_]F4"I]SCV5]!?Y_ E\6PC/',3 +HBS%Z"N.0-+Q((
M3(<M3(<-,Z?'=:'!V$_B[/5$E; O;C[=1OL,/LC,9NSW16]:DE%C^Z_6[G:S
M U@9.VF.7^"6)^.)-V26<)7!E%E@JU+#DQJSB -Z&2BEO$&/@;D,>1R.^J"5
MA4$#E(<VBP N0-_<NBZG.TRGVT]7<Y"M9K;8E=W?MTWW>H"$' N\;8J2ID5,
M(#!3F04H?ARN0&=X )@'@D33)32_(C !XJ7TYY.1\%*N-GC"H!>*T1J[%8D8
M.?'G")4]N(M,/P65*N%(!&HY6NYB3R""@Y:C11QT02Q)&'B4CH@V:Y.^9WE
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M<JG12OY//KE.UUL56;)"9PH?$$C[6_\/4$L#!!0    ( +> ,%/;6E:!; (
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M=\L[7*[-]]X"6L%FJV>C7U!+ P04    " "W@#!34NPI:[0*   !80  %0
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MLH>T":W(;"Z(%9T&P(F7Y>9'T_&V!-.X1-\:5[)T]W[!+^>(J A+$9EVE00
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M)!Q[AJQ?_%9B;8W529Y-3Z,)LC6 N@3;#>Q%MWEZ^O&1P=]XH>92<HUC%8-
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MG?%SLW7Z8K,G67TS__3%_P%02P,$%     @ MX P4VNOG SA!@  \3(  !4
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M?5G>E<B:)5/<)S9+(-&2@Y!=)I.X!$0,GAD5+!-F% O/FAT&PX1+CN/%W/;
M4!5YR%L:U'ZE!6Z=NV))""<ZR1AD:4HL!\7!)9FDS%9@IBSS.+*8]-3F, XF
M7%T<*>.6(3BML2,8RX#]_HQN:T_]/B,_EJB,\TS%;BM85QQUJNN%@^ M<R*)
M2F7C-KB\;'L8%!.N+FY(UFG!<=PTEUA_WQ?O@^69[S:ZB8S6/LJ!EQ@!F4JB
M3[REF7"3B#SQ8!@H$ZXT;E3B250;WZZQ7M%H^)^ZNFK/J7,7KKQ9.I,(1D,?
M2)\R$-9&\!H9<"$S%:B3VHU;;?R%\6$;IR9?;QPO["3X."+):E<<$^+7O^#-
MTM(2BM(B2I:$D""8". SP2%)E3>933G'33RH>&1V&!,3+D&.%W/+-!S2>!>[
M,>]=X5;+J*0,ECK/;&()8]>MIZ($[2.7QC&!,8ZBX(&Y8=&?<!7R]>)M^Z'#
M9=TI]"YO@BO^1%??[P.USE)NW&V;]X'(30+ES$$A1)M&U%I['ORX!Q O6![&
MPH1+DAN1=&-8O%D\T?&$#ASLW/W0O73_(W&P\S]02P$"% ,4    " "W@#!3
ME)/Y$1H9   ?<0  '               @ $     97-M;VUA:&]G86YY<')E
M<W-R96QE87-E+FAT;5!+ 0(4 Q0    ( +> ,%/0N0:,YQ,  (1/   :
M          "  509  !E<VUO;6=C,#$X<')E<W-R96QE87-E+FAT;5!+ 0(4
M Q0    ( +> ,%-I6IFPZ!0  )R,   1              "  7,M  !M9VYX
M+3(P,C$P.3$V+FAT;5!+ 0(4 Q0    ( +> ,%/;6E:!; (  &L'   1
M          "  8I"  !M9VYX+3(P,C$P.3$V+GAS9%!+ 0(4 Q0    ( +>
M,%-2["EKM H   %A   5              "  25%  !M9VYX+3(P,C$P.3$V
M7VQA8BYX;6Q02P$"% ,4    " "W@#!3:Z^<#.$&  #Q,@  %0
M    @ $,4   ;6=N>"TR,#(Q,#DQ-E]P<F4N>&UL4$L%!@     &  8 E@$
' "!7      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
